Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD February 28, 2023 GlobeNewswire Source: Medical Share on Facebook Share Share on TwitterTweet Share on Google Plus Share Share on Pinterest Share Share on LinkedIn Share Share on Digg Share